Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Delisting Risk Hits I-Mab Hard, Bilateral Agreement Needed?

Switching Auditors Not Ultimate Solution

Executive Summary

It started with the risk of delisting from US stock markets over auditing requirements, but there are other underlying risks for Chinese bioventures that ultimately only some form of bilateral governmental agreement may need to address, but this may be increasingly hard to reach.

You may also be interested in...



China Regulatory Express: Patent Linkage, Data Protection, Bio Five-Year Plan

Important changes are coming to China's Drug Administration Law as the government aims to address through several revisions a number of key issues since the law’s original enactment in 2019.

As WHO Rings COVID Zero Alarm, Study Says China Vaccination 'Insufficient'

The WHO calls the "COVID Zero" containment policy that Beijing is doubling down on "unsustainable," while a new study has shed light on the potential cost of moving away from cutting transmissions to mitigating disease. 

Will Yabao Help Lupin’s Attempts To Scale The Great Wall?

With the Yabao partnership, Lupin builds on a toehold gained through the Foncoo tie-up as it attempts to scale the market behind the Great Wall of China. Scrip takes a look at possible approaches and potential of the partnership

Topics

Related Companies

UsernamePublicRestriction

Register

SC146360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel